The purpose of this study is to evaluate of efficacy and safety of mometasone furoate plus azelastine HCl in patients with perennial allergic rhinitis.

Inclusion Criteria:

• Patients over 12 years of age
• Medical history of perennial allergic rhinitis for at least two years
• Moderate ro severe nasal symptom (during placebo run-in period AM rTNSS or PM rTNSS≥8)
• Positive skin prick test result within the previous 12 months

Exclusion Criteria:

• patients with active asthma that required therapy with inhaled or oral corticosteroids or long-term β-agonist
• patients with severe rhinostenosis, severely deviated nasal septum or local infection on the nasal mucous membrane
• patients with herpes zoster, glaucoma or cataract
• patients with history of operation or damage on nasal cavity or ocular region
• patients with drug-induced rhinitis
• patients with history of respiratory infection which requires antibiotic therapy within the previous 14 days
• Patients with lung disease including COPD
• Patients with history of immunotherapy or ongoing immunotherapy
• patients administered with super potent or potent corticosteroid
• patients administered with intra-muscular or intra-articular steroid within the previous 3 months
• patients administered with subcutaneous omalizumab within the previous 5 months